Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A trial to evaluate patient perceived experience with Collagenase clostridium histolyticum injection for Peyronie's disease in a clinical practice

Next Previous
X
Search
Trial Profile

A trial to evaluate patient perceived experience with Collagenase clostridium histolyticum injection for Peyronie's disease in a clinical practice

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Jul 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Collagenase clostridium histolyticum (Primary)
  • Indications Peyronie's disease
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 01 Jun 2021 Primary endpoint has been met (Interval-to-final curvature improvements stratified by 10/10 or 20%/20% improvements achieved during the baseline-to-interval period) , according to Results published in the Journal of Sexual Medicine
    • 01 Jun 2021 Results published in the Journal of Sexual Medicine
    • 22 Mar 2019 Results assessing the safety and efficacy of Collagenase Clostridium Histolyticum in Peyronie's Disease Men with Ventral Curvatures (n=228) published in the Urology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top